Perspective Therapeutics Inc. has announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a radiopharmaceutical candidate for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). The results were presented as a poster at the 2026 ASCO Gastrointestinal Cancers Symposium. The updated data, with approximately 13 weeks of additional follow-up, indicate that [212Pb]VMT-α-NET continues to be well-tolerated. In Cohort 2, an objective response was observed in 39% of patients regardless of SSTR2 expression profile. The dose limiting toxicity (DLT) assessment for Cohort 3 (6.0 mCi) was completed as planned, allowing further patient enrollment at this dose. Additional efficacy data from Cohort 2 and Cohort 3 are pending, and further submissions to medical conferences and regulatory engagements are planned for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622725-en) on January 09, 2026, and is solely responsible for the information contained therein.